Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	Daily Top 10 COVID-19 papers DEU | ENG | ESP | FRA | ITA | POR | TUR | VNM

Vaccines

Free Subscription Articles published in Lancet Retrieve available abstracts of 115 articles: HTML format

Single Articles

May 2020
1. WHITEHEAD CL, Walker SP
   Consider pregnancy in COVID-19 therapeutic drug and vaccine trials.
   Lancet. 2020 May 13. pii: S0140-6736(20)31029.
   PubMed    
   
   
   
2. PHELAN AL
   COVID-19 immunity passports and vaccination certificates: scientific, equitable, and legal challenges.
   Lancet. 2020 May 4. pii: S0140-6736(20)31034.
   PubMed    
   
   
   April 2020
3. CURTIS N, Sparrow A, Ghebreyesus TA, Netea MG, et al
   Considering BCG vaccination to reduce the impact of COVID-19.
   Lancet. 2020 Apr 30. pii: S0140-6736(20)31025.
   PubMed    
   
   
   
4. KEATING C
   The history of the RTS,S/AS01 malaria vaccine trial.
   Lancet. 2020;395:1336-1337.
   PubMed    
   
   
   
5. LANE R
   Sarah Gilbert: carving a path towards a COVID-19 vaccine.
   Lancet. 2020;395:1247.
   PubMed    
   
   
   
6. THE LANCET
   A new roadmap for meningitis.
   Lancet. 2020;395:1230.
   PubMed    
   
   
   
7. ALFARO-MURILLO JA, Avila-Aguero ML, Fitzpatrick MC, Crystal CJ, et al
   The case for replacing live oral polio vaccine with inactivated vaccine in the Americas.
   Lancet. 2020;395:1163-1166.
   PubMed    
   
   
   March 2020
8. YAMEY G, Schaferhoff M, Hatchett R, Pate M, et al
   Ensuring global access to COVID-19 vaccines.
   Lancet. 2020 Mar 31. pii: S0140-6736(20)30763.
   PubMed    
   
   
   
9. MEMISH ZA, Perlman S, Van Kerkhove MD, Zumla A, et al
   Middle East respiratory syndrome.
   Lancet. 2020;395:1063-1077.
   PubMed     Abstract available
   
   
   
10. TRICOU V, Saez-Llorens X, Yu D, Rivera L, et al
    Safety and immunogenicity of a tetravalent dengue vaccine in children aged 2-17 years: a randomised, placebo-controlled, phase 2 trial.
    Lancet. 2020 Mar 17. pii: S0140-6736(20)30556.
    PubMed     Abstract available
    
    
    
11. WILDER-SMITH A
    Evaluation of a tetravalent dengue vaccine by serostatus and serotype.
    Lancet. 2020 Mar 17. pii: S0140-6736(20)30603.
    PubMed    
    
    
    
12. BISWAL S, Borja-Tabora C, Martinez Vargas L, Velasquez H, et al
    Efficacy of a tetravalent dengue vaccine in healthy children aged 4-16 years: a randomised, placebo-controlled, phase 3 trial.
    Lancet. 2020 Mar 17. pii: S0140-6736(20)30414.
    PubMed     Abstract available
    
    
    
13. ZAROCOSTAS J
    Hope for the Ebola outbreak in DR Congo.
    Lancet. 2020;395:773.
    PubMed    
    
    
    February 2020
14. FIDLER S, Stohr W, Pace M, Dorrell L, et al
    Antiretroviral therapy alone versus antiretroviral therapy with a kick and kill approach, on measures of the HIV reservoir in participants with recent HIV infection (the RIVER trial): a phase 2, randomised trial.
    Lancet. 2020 Feb 18. pii: S0140-6736(19)32990.
    PubMed     Abstract available
    
    
    
15. PHUMAPHI J, Gautam KC, Mason E
    Increased production and comprehensive guidelines needed for HPV vaccine.
    Lancet. 2020;395:319-321.
    PubMed    
    
    
    January 2020
16. BRISSON M, Kim JJ, Canfell K, Drolet M, et al
    Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries.
    Lancet. 2020 Jan 30. pii: S0140-6736(20)30068.
    PubMed     Abstract available
    
    
    
17. CANFELL K, Kim JJ, Brisson M, Keane A, et al
    Mortality impact of achieving WHO cervical cancer elimination targets: a comparative modelling analysis in 78 low-income and lower-middle-income countries.
    Lancet. 2020 Jan 30. pii: S0140-6736(20)30157.
    PubMed     Abstract available
    
    
    
18. BROTONS M, Bruni L
    Population-level impact of human papillomavirus vaccination.
    Lancet. 2020 Jan 20. pii: S0140-6736(19)33153.
    PubMed    
    
    
    
19. SASIENI P, Cuzick J
    Population-level impact of human papillomavirus vaccination.
    Lancet. 2020 Jan 20. pii: S0140-6736(19)33109.
    PubMed    
    
    
    
20. DROLET M, Brisson M
    Population-level impact of human papillomavirus vaccination - Authors' reply.
    Lancet. 2020 Jan 20. pii: S0140-6736(19)33158.
    PubMed    
    
    
    
21. MIYACHI T, Takita M, Senoo Y, Yamamoto K, et al
    Lower trust in national government links to no history of vaccination.
    Lancet. 2020;395:31-32.
    PubMed    
    
    
    December 2019
22. WILDER-SMITH A, Flasche S, Smith PG
    Vaccine-attributable severe dengue in the Philippines.
    Lancet. 2019;394:2151-2152.
    PubMed    
    
    
    
23. HOLT E
    Global surge in measles should be "a wake-up call".
    Lancet. 2019;394:2137.
    PubMed    
    
    
    
24. BEKKER LG, Tatoud R, Dabis F, Feinberg M, et al
    The complex challenges of HIV vaccine development require renewed and expanded global commitment.
    Lancet. 2019 Dec 2. pii: S0140-6736(19)32682.
    PubMed    
    
    
    November 2019
25. BURKI T
    Ebola virus vaccine receives prequalification.
    Lancet. 2019;394:1893.
    PubMed    
    
    
    
26. SHUSTER S
    The life improvement value: a new measure of cost-efficiency.
    Lancet. 2019;394:1903-1904.
    PubMed    
    
    
    
27. MAKRI A
    Progress lags on vaccines to beat antimicrobial resistance.
    Lancet. 2019;394:1793-1794.
    PubMed    
    
    
    October 2019
28. THORNTON J
    Polio returns to the Philippines.
    Lancet. 2019;394:1217.
    PubMed    
    
    
    September 2019
29. ALI M, Ahmad N, Khan H, Ali S, et al
    Polio vaccination controversy in Pakistan.
    Lancet. 2019;394:915-916.
    PubMed    
    
    
    
30. REUTER A, Hughes J, Furin J
    Challenges and controversies in childhood tuberculosis.
    Lancet. 2019;394:967-978.
    PubMed     Abstract available
    
    
    August 2019
31. LOH LC
    Mandatory reporting and vaccination in North America.
    Lancet. 2019 Aug 13. pii: S0140-6736(19)31253.
    PubMed    
    
    
    July 2019
32. ZAROCOSTAS J
    Ebola outbreak declared a PHEIC, world waits for next steps.
    Lancet. 2019;394:287-288.
    PubMed    
    
    
    
33. ADEPOJU P
    The yellow fever vaccination certificate loophole in Nigeria.
    Lancet. 2019;394:203-204.
    PubMed    
    
    
    
34. SCHUERMAN L
    RTS,S malaria vaccine could provide major public health benefits.
    Lancet. 2019 Jul 9. pii: S0140-6736(19)31567.
    PubMed    
    
    
    
35. NAKKAZI E
    Apply to trial Ebola vaccines in DR Congo, says ministry.
    Lancet. 2019;394:15-16.
    PubMed    
    
    
    June 2019
36. DROLET M, Benard E, Perez N, Brisson M, et al
    Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis.
    Lancet. 2019 Jun 26. pii: S0140-6736(19)30298.
    PubMed     Abstract available
    
    
    
37. DE SANJOSE S, Delany-Moretlwe S
    HPV vaccines can be the hallmark of cancer prevention.
    Lancet. 2019 Jun 26. pii: S0140-6736(19)30549.
    PubMed    
    
    
    
38. MORI Y, Katasako A, Matsunaga S, Matono T, et al
    Tetanus: remember to vaccinate.
    Lancet. 2019;393:2331.
    PubMed    
    
    
    
39. THOMPSON KM
    Polio endgame options: will we have the vaccines needed?
    Lancet. 2019 Jun 4. pii: S0140-6736(19)31294.
    PubMed    
    
    
    
40. VAN DAMME P, De Coster I, Bandyopadhyay AS, Revets H, et al
    The safety and immunogenicity of two novel live attenuated monovalent (serotype 2) oral poliovirus vaccines in healthy adults: a double-blind, single-centre phase 1 study.
    Lancet. 2019 Jun 4. pii: S0140-6736(19)31279.
    PubMed     Abstract available
    
    
    May 2019
41. THE LANCET
    Acknowledging the limits of public health solutions.
    Lancet. 2019;393:2100.
    PubMed    
    
    
    
42. USHER AD
    Low-cost pneumonia vaccine breaks into global market.
    Lancet. 2019;393:2025-2026.
    PubMed    
    
    
    
43. ROBERT A, Funk S, Kucharski AJ
    The measles crisis in Europe-the need for a joined-up approach.
    Lancet. 2019;393:2033.
    PubMed    
    
    
    
44. SNIDER CJ, Zaman K, Estivariz CF, Yunus M, et al
    Immunogenicity of full and fractional dose of inactivated poliovirus vaccine for use in routine immunisation and outbreak response: an open-label, randomised controlled trial.
    Lancet. 2019 May 16. pii: S0140-6736(19)30503.
    PubMed     Abstract available
    
    
    
45. SUTTER RW, Zaffran M
    Addressing the inactivated poliovirus vaccine shortage.
    Lancet. 2019 May 16. pii: S0140-6736(19)30766.
    PubMed    
    
    
    
46. DE FIGUEIREDO A, Were F
    Local trends in immunisation coverage across Africa.
    Lancet. 2019;393:1779-1781.
    PubMed    
    
    
    April 2019
47. ADEPOJU P
    RTS,S malaria vaccine pilots in three African countries.
    Lancet. 2019;393:1685.
    PubMed    
    
    
    
48. HAMMITT LL, Etyang AO, Morpeth SC, Ojal J, et al
    Effect of ten-valent pneumococcal conjugate vaccine on invasive pneumococcal disease and nasopharyngeal carriage in Kenya: a longitudinal surveillance study.
    Lancet. 2019 Apr 15. pii: S0140-6736(18)33005.
    PubMed     Abstract available
    
    
    
49. KLUGMAN KP, Rodgers GL
    Population versus individual protection by pneumococcal conjugate vaccination.
    Lancet. 2019 Apr 15. pii: S0140-6736(19)30039.
    PubMed    
    
    
    
50. MOSSER JF, Gagne-Maynard W, Rao PC, Osgood-Zimmerman A, et al
    Mapping diphtheria-pertussis-tetanus vaccine coverage in Africa, 2000-2016: a spatial and temporal modelling study.
    Lancet. 2019 Apr 5. pii: S0140-6736(19)30226.
    PubMed     Abstract available
    
    
    March 2019
51. NAYAR RK, Nair AT, Shaffi M, Swarnam K, et al
    Methods to overcome vaccine hesitancy.
    Lancet. 2019;393:1203-1204.
    PubMed    
    
    
    
52. THE LANCET
    Canada's mandatory vaccination reporting plans.
    Lancet. 2019;393:960.
    PubMed    
    
    
    
53. ZHAO F, Qiao Y
    Cervical cancer prevention in China: a key to cancer control.
    Lancet. 2019;393:969-970.
    PubMed    
    
    
    
54. MALVY D, McElroy AK, de Clerck H, Gunther S, et al
    Ebola virus disease.
    Lancet. 2019;393:936-948.
    PubMed     Abstract available
    
    
    
55. GAUDINSKI MR, Coates EE, Novik L, Widge A, et al
    Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study.
    Lancet. 2019;393:889-898.
    PubMed     Abstract available
    
    
    February 2019
56. GOSTIN L, Phelan A, Coutinho AG, Eccleston-Turner M, et al
    Ebola in the Democratic Republic of the Congo: time to sound a global alert?
    Lancet. 2019 Feb 1. pii: S0140-6736(19)30243.
    PubMed    
    
    
    January 2019
57. WILDER-SMITH A, Ooi EE, Horstick O, Wills B, et al
    Dengue.
    Lancet. 2019;393:350-363.
    PubMed     Abstract available
    
    
    
58. COHEN PA, Jhingran A, Oaknin A, Denny L, et al
    Cervical cancer.
    Lancet. 2019;393:169-182.
    PubMed     Abstract available
    
    
    
59. THE LANCET
    Cervical cancer: unequal progress.
    Lancet. 2019;393:104.
    PubMed    
    
    
    
60. SHUCHMAN M
    Logistical challenges in the DR Congo Ebola virus response.
    Lancet. 2019;393:117-118.
    PubMed    
    
    
    November 2018
61. LARSON HJ
    The state of vaccine confidence.
    Lancet. 2018;392:2244-2246.
    PubMed    
    
    
    
62. THE LANCET
    Looking beyond the Decade of Vaccines.
    Lancet. 2018;392:2139.
    PubMed    
    
    
    
63. CHANDLER J
    Fighting a polio outbreak in Papua New Guinea.
    Lancet. 2018;392:2155-2156.
    PubMed    
    
    
    
64. POWERS AM
    Licensed chikungunya virus vaccine: a possibility?
    Lancet. 2018 Nov 5. pii: S0140-6736(18)32809.
    PubMed    
    
    
    
65. REISINGER EC, Tschismarov R, Beubler E, Wiedermann U, et al
    Immunogenicity, safety, and tolerability of the measles-vectored chikungunya virus vaccine MV-CHIK: a double-blind, randomised, placebo-controlled and active-controlled phase 2 trial.
    Lancet. 2018 Nov 5. pii: S0140-6736(18)32488.
    PubMed     Abstract available
    
    
    October 2018
66. CLAUDE KM, Underschultz J, Hawkes MT
    Ebola virus epidemic in war-torn eastern DR Congo.
    Lancet. 2018;392:1399-1401.
    PubMed    
    
    
    
67. MARKS F, Kim JH, Rakotozandrindrainy R
    Madagascar should introduce typhoid conjugate vaccines now.
    Lancet. 2018;392:1309-1310.
    PubMed    
    
    
    September 2018
68. ZIMMER BL, Gamble L, Mayer D, Foster R, et al
    Canine rabies vaccination reduces child rabies cases in Malawi.
    Lancet. 2018;392:1115-1116.
    PubMed    
    
    
    
69. PRUE G, Baker P, Graham D, Nutting C, et al
    It is time for universal HPV vaccination.
    Lancet. 2018;392:913-914.
    PubMed    
    
    
    
70. BURKI T
    Cochrane review methods called into question.
    Lancet. 2018;392:906.
    PubMed    
    
    
    
71. HOLT E
    41 000 measles cases in Europe since the beginning of 2018.
    Lancet. 2018;392:724.
    PubMed    
    
    
    August 2018
72. HAYFLICK L
    Subject of The Vaccine Race offers perspective on errors.
    Lancet. 2018;392:633-634.
    PubMed    
    
    
    
73. LEVY Y, Lane C, Piot P, Beavogui AH, et al
    Prevention of Ebola virus disease through vaccination: where we are in 2018.
    Lancet. 2018 Aug 10. pii: S0140-6736(18)31710.
    PubMed    
    
    
    
74. THE LANCET
    Vaccine scandal and confidence crisis in China.
    Lancet. 2018;392:360.
    PubMed    
    
    
    
75. GREEN A
    HPV vaccine to be offered to boys in England.
    Lancet. 2018;392:374.
    PubMed    
    
    
    
76. YUAN X
    China's vaccine production scare.
    Lancet. 2018;392:371.
    PubMed    
    
    
    
77. FRASER B
    Measles outbreak in the Americas.
    Lancet. 2018;392:373.
    PubMed    
    
    
    July 2018
78. BAROUCH DH, Tomaka FL, Wegmann F, Stieh DJ, et al
    Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19).
    Lancet. 2018;392:232-243.
    PubMed     Abstract available
    
    
    
79. PAVLAKIS GN, Felber BK
    A new step towards an HIV/AIDS vaccine.
    Lancet. 2018;392:192-194.
    PubMed    
    
    
    
80. LEWNARD JA
    Ebola virus disease: 11 323 deaths later, how far have we come?
    Lancet. 2018;392:189-190.
    PubMed    
    
    
    
81. DEVI S
    Setbacks in the fight to eradicate polio.
    Lancet. 2018;392:201-202.
    PubMed    
    
    
    
82. BANYAI K, Estes MK, Martella V, Parashar UD, et al
    Viral gastroenteritis.
    Lancet. 2018;392:175-186.
    PubMed     Abstract available
    
    
    June 2018
83. GREEN A
    DR Congo: investigational research against Ebola virus.
    Lancet. 2018;391:2308-2309.
    PubMed    
    
    
    May 2018
84. WINSTON DJ, Mullane KM, Cornely OA, Boeckh MJ, et al
    Inactivated varicella zoster vaccine in autologous haemopoietic stem-cell transplant recipients: an international, multicentre, randomised, double-blind, placebo-controlled trial.
    Lancet. 2018;391:2116-2127.
    PubMed     Abstract available
    
    
    
85. CORCORAN B, Clarke A, Barrett T
    Rapid response to HPV vaccination crisis in Ireland.
    Lancet. 2018;391:2103.
    PubMed    
    
    
    
86. MACARTNEY K, Gershon AA
    Shingles vaccine after auto-HSCT decreases risk.
    Lancet. 2018;391:2082-2084.
    PubMed    
    
    
    
87. KELLY JD, Mukadi P, Dhillon RS
    Beyond vaccines: improving survival rates in the DRC Ebola outbreak.
    Lancet. 2018 May 25. pii: S0140-6736(18)31212.
    PubMed    
    
    
    
88. QADRI F, Azad AK, Flora MS, Khan AI, et al
    Emergency deployment of oral cholera vaccine for the Rohingya in Bangladesh.
    Lancet. 2018;391:1877-1879.
    PubMed    
    
    
    
89. AGUIAR M
    Dengue vaccination: a more ethical approach is needed.
    Lancet. 2018;391:1769-1770.
    PubMed    
    
    
    
90. HARGREAVES S, Nellums LB, Ramsay M, Saliba V, et al
    Who is responsible for the vaccination of migrants in Europe?
    Lancet. 2018;391:1752-1754.
    PubMed    
    
    
    April 2018
91. THE LANCET
    Addressing decreasing vaccine coverage in the EU.
    Lancet. 2018;391:1638.
    PubMed    
    
    
    
92. CHEN S, Li J, Wang D, Fung H, et al
    The hepatitis B epidemic in China should receive more attention.
    Lancet. 2018;391:1572.
    PubMed    
    
    
    March 2018
93. PENG X, Hu X, Salazar MA
    On reducing the risk of vaccine-associated paralytic poliomyelitis in the global transition from oral to inactivated poliovirus vaccine.
    Lancet. 2018 Mar 28. pii: S0140-6736(18)30483.
    PubMed    
    
    
    
94. WATTS G
    New York Challenge sets high bar for HPV vaccination.
    Lancet. 2018;391:1137.
    PubMed    
    
    
    
95. METZGER WG, Vivas-Martinez S
    Questionable efficacy of the rVSV-ZEBOV Ebola vaccine.
    Lancet. 2018;391:1021.
    PubMed    
    
    
    
96. LONGINI IM, Rottingen JA, Kieny MP, Edmunds WJ, et al
    Questionable efficacy of the rVSV-ZEBOV Ebola vaccine - Authors' reply.
    Lancet. 2018;391:1021-1022.
    PubMed    
    
    
    February 2018
97. PANG T, Gubler D, Goh DYT, Ismail Z, et al
    Dengue vaccination: a more balanced approach is needed.
    Lancet. 2018;391:654.
    PubMed    
    
    
    
98. LARSON HJ
    A global girl gang.
    Lancet. 2018;391:527-528.
    PubMed    
    
    
    
99. PAULES CI, Subbarao K
    Influenza vaccination and prevention of cardiovascular disease mortality - Authors' reply.
    Lancet. 2018;391:427-428.
    PubMed    
    
    
    
100. CALDEIRA D, Ferreira JJ, Costa J
     Influenza vaccination and prevention of cardiovascular disease mortality.
     Lancet. 2018;391:426-427.
     PubMed    
     
     
     
101. THE LANCET
     Yellow fever: a major threat to public health.
     Lancet. 2018;391:402.
     PubMed    
     
     
     January 2018
102. THE LANCET
     Preparing for seasonal influenza.
     Lancet. 2018;391:180.
     PubMed    
     
     
     
103. THE LANCET
     A new vaccine for typhoid control.
     Lancet. 2018;391:96.
     PubMed    
     
     
     
104. PETOUSIS-HARRIS H, Paynter J, Morgan J, Saxton P, et al
     Pitfalls of the healthy vaccinee effect - Authors' reply.
     Lancet. 2018;391:123-124.
     PubMed    
     
     
     
105. MAHMUD SM, Righolt CH
     Pitfalls of the healthy vaccinee effect.
     Lancet. 2018;391:123.
     PubMed    
     
     
     
106. ZAFFRAN M, McGovern M, Hossaini R, Martin R, et al
     The polio endgame: securing a world free of all polioviruses.
     Lancet. 2018;391:11-13.
     PubMed    
     
     
     December 2017
107. MARQUES ETA, Burke DS
     Tradition and innovation in development of a Zika vaccine.
     Lancet. 2017 Dec 4. pii: S0140-6736(17)33107.
     PubMed    
     
     
     
108. GAUDINSKI MR, Houser KV, Morabito KM, Hu Z, et al
     Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials.
     Lancet. 2017 Dec 4. pii: S0140-6736(17)33105.
     PubMed     Abstract available
     
     
     
109. MODJARRAD K, Lin L, George SL, Stephenson KE, et al
     Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trials.
     Lancet. 2017 Dec 4. pii: S0140-6736(17)33106.
     PubMed     Abstract available
     
     
     October 2017
110. YIN Y
     HPV vaccination in China needs to be more cost-effective.
     Lancet. 2017;390:1735-1736.
     PubMed    
     
     
     September 2017
111. JIN C, Gibani MM, Moore M, Juel HB, et al
     Efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of Salmonella Typhi: a randomised controlled, phase 2b trial.
     Lancet. 2017 Sep 28. pii: S0140-6736(17)32149.
     PubMed     Abstract available
     
     
     
112. FEASEY NA, Levine MM
     Typhoid vaccine development with a human challenge model.
     Lancet. 2017 Sep 28. pii: S0140-6736(17)32407.
     PubMed    
     
     
     
113. HUH WK, Joura EA, Giuliano AR, Iversen OE, et al
     Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trial.
     Lancet. 2017 Sep 5. pii: S0140-6736(17)31821.
     PubMed     Abstract available
     
     
     
114. DENNY L
     Nine-valent human papillomavirus vaccine: great science, but will it save lives?
     Lancet. 2017 Sep 5. pii: S0140-6736(17)32144.
     PubMed    
     
     
     November 2016
115. DENNY L, de Sanjose S, Mutebi M, Anderson BO, et al
     Interventions to close the divide for women with breast and cervical cancer between low-income and middle-income countries and high-income countries.
     Lancet. 2016 Nov 1. pii: S0140-6736(16)31795.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Vaccines is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: